A new experimental vaccine, ELI-002 2P, has shown groundbreaking results in early clinical trials, demonstrating potential to prevent the recurrence of pancreatic and colorectal cancers. The findings, recently published in Nature Medicine, have attracted significant attention in the oncology community.
High-Risk Cancers with Limited Options
Pancreatic and colorectal cancers are among the most lethal malignancies, with high recurrence rates even after surgery and standard adjuvant therapy. Preventing residual cancer cells from re-emerging has long been one of the greatest clinical challenges.
How ELI-002 2P Works
Developed by U.S.-based Elicio Therapeutics, ELI-002 2P is an off-the-shelf cancer vaccine designed to target common mutations in the KRAS gene. KRAS is a well-known “driver mutation” found in multiple cancers, present in more than 90% of pancreatic cancer patients.
The vaccine works by activating the patient’s own T-cell immune response, training the immune system to recognize and eliminate residual cancer cells, thereby reducing the risk of relapse. Unlike personalized mRNA vaccines that must be custom-made for each patient, ELI-002 offers a cost-effective and scalable approach, making it more feasible for broad clinical use.
Promising Trial Results
In a Phase I trial involving 25 patients with post-surgical pancreatic or colorectal cancer, 84% mounted strong KRAS-specific T-cell responses. Patients with the strongest immune activation showed a markedly reduced risk of relapse. In some cases, blood biomarkers of minimal residual disease were completely cleared, suggesting the possibility of eliminating microscopic tumor remnants.
A Step Toward Universal Cancer Vaccines
Experts highlight that the significance of ELI-002 2P lies not only in its early clinical efficacy but also in its proof-of-concept: cancer vaccines may move beyond personalized, costly, and time-consuming approaches toward more universal and scalable solutions.
Elicio Therapeutics has already launched a Phase II clinical trial with the ELI-002 7P version, aiming to validate safety and efficacy in a larger patient population. If successful, the vaccine could become one of the world’s first generalized cancer vaccines proven to reduce recurrence rates.
